These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28530791)

  • 1. Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras.
    Novotny CJ; Hamilton GL; McCormick F; Shokat KM
    ACS Chem Biol; 2017 Jul; 12(7):1956-1962. PubMed ID: 28530791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC; Hamilton AD; Sebti SM
    Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
    Mazet JL; Padieu M; Osman H; Maume G; Mailliet P; Dereu N; Hamilton AD; Lavelle F; Sebti SM; Maume BF
    FEBS Lett; 1999 Oct; 460(2):235-40. PubMed ID: 10544242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
    Morgan MA; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.
    James G; Goldstein JL; Brown MS
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4454-8. PubMed ID: 8633088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitor as anticancer agent.
    Agrawal AG; Somani RR
    Mini Rev Med Chem; 2009 Jun; 9(6):638-52. PubMed ID: 19519490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.
    Brock EJ; Ji K; Reiners JJ; Mattingly RR
    Mini Rev Med Chem; 2016; 16(5):358-69. PubMed ID: 26423696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photochemical modulation of Ras-mediated signal transduction using caged farnesyltransferase inhibitors: activation by one- and two-photon excitation.
    Abate-Pella D; Zeliadt NA; Ochocki JD; Warmka JK; Dore TM; Blank DA; Wattenberg EV; Distefano MD
    Chembiochem; 2012 May; 13(7):1009-16. PubMed ID: 22492666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
    Sebti SM; Hamilton AD
    Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
    Sousa SF; Fernandes PA; Ramos MJ
    Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways.
    Kim CK; Choi YK; Lee H; Ha KS; Won MH; Kwon YG; Kim YM
    Mol Pharmacol; 2010 Jul; 78(1):142-50. PubMed ID: 20406854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
    Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.